Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 10/20 | 0.48 |
| ▸ | GRM5 | P41594 | 9/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | IDH2 | P48735 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31379876 | 0.87 | GRM1 (0.48) | GRM1GRM5NAMPTPDK4JAK2 | |
| SCHEMBL31379877 | 0.83 | JAK3 (0.51) | IDH2JAK2JAK3PTK2 | |
| SCHEMBL31379900 | 0.83 | APP (0.48) | GRM1GRM5NAMPTPDK4IDH2 | |
| SCHEMBL31379912 | 0.82 | SCN9A (0.45) | GRM1GRM5NAMPTPDK4IDH2 | |
| SCHEMBL31379922 | 0.80 | NAMPT (0.41) | GRM1GRM5NAMPTPDK4IDH2 | |
| SCHEMBL31379870 | 0.80 | GRM5 (0.42) | GRM1GRM5NAMPTPDK4JAK2 | |
| SCHEMBL31379931 | 0.80 | GRM1 (0.58) | GRM1GRM5NAMPTPDK4TNK2 | |
| SCHEMBL31379871 | 0.79 | JAK2 (0.43) | GRM1GRM5NAMPTPDK4IDH2 | |
| SCHEMBL31379867 | 0.79 | JAK2 (0.41) | GRM1GRM5NAMPTPDK4IDH2 | |
| SCHEMBL31379887 | 0.78 | SCN9A (0.42) | GRM1GRM5NAMPTPDK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025027560-A1 | NEW RHOJ/CDC42 INHIBITORS DEVELOPED FOR THE TREATMENT OF CANCER, BENIGN TUMORS, RETINAL DISORDERS, VASCULAR DISORDERS, AND CARDIOMYOPATHIES | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-02-06 | — | — | WO | disclosed |